Voyager Therapeutics appoints Grace E. Colón, Ph.D. to board of directors, effective Jan 1, 2023

Voyager Therapeutics, Inc.

Grace E. Colón appointed as Class I director; term runs until 2025 annual meeting.
Annual cash retainer of $40,000 for board service; $6,000 for Compensation Committee membership.
Initial option grant of 44,000 shares vesting quarterly over four years; annual option of 22,000 shares thereafter.
Dr. Colón also serves as Executive Chair of ProterixBio and director of CareDx; no family relationships with officers.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Grace E. Colón

director

VYGR · Voyager Therapeutics, Inc.

Effective: 2023-01-01
Filed: December 14, 2022, 6:59 PM ET

appointed Grace E. Colón, Ph.D. as a director of the Company and as a member of the Compensation Committee of the Board, effective January 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Grace E. Colón was appointed as director at Voyager Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

appointed Grace E. Colón, Ph.D. as a director of the Company and as a member of the Compensation Committee of the Board, effective January 1, 2023.

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-126797

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.